Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China.
Li Bai(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoyuan Xu(Columbia University), Zhenru Feng(Peking University), Ming‐Lung Yu(National Sun Yat-sen University), Wengang Li(Xiamen University), Haiying Lu(Shanghai University of Traditional Chinese Medicine)
PubMed
January 5, 2009
Cited by 27
Related Papers
Treatment of chronic hepatitis C in Asia: When East meets West
|Journal of Gastroenterology and Hepatology|2009|262
RAGE Regulates the Metabolic and Inflammatory Response to High-Fat Feeding in Mice
|Diabetes|2014|202
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease
|Journal of Hepatology|2021|118
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus
|Metabolism|2024|111
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B
|The American Journal of Gastroenterology|2019|102